.Attributes Medicine, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA permission after a damaging trial, which highlights the numerous complications and difficulties of medicine growth in this particular setting.